Medical Oncology Provider Experience



March 14, 2025

© 2025 eviCore healthcare. All Rights Reserved. This presentation contains Confidential and Proprietary information. Use and distribution limited solely to authorized personnel.

Agenda:

Solutions Overview

Submitting Requests

Prior Authorization Outcomes, Special Considerations & Post-Decision Options

EviCore Provider Portal Overview, Features, and Benefits

Provider Resources

Questions & Next Steps

Appendix

- Step-by-Step Case Submission
- Self-Service Peer-to-Peer Scheduling Tool



Solution Overview



© 2025 eviCore healthcare. All Rights Reserved. This presentation contains Confidential and Proprietary information. Use and distribution limited solely to authorized personnel.

Applicable Memberships

- + Medicare
- + 65 Plus Plan (HMO)
- + Coordinated Benefits Plan (HMO)
- + Increased Benefits Plan (HMO)
- + CompleteCare (HMO D-SNP)
- + Connection Plan (HMO D-SNP)
- + Life Improvement Plan (HMO D-SNP)
- + Signature (HMO)
- + Signature (PPO)
- + Medicaid Managed Care
- + Child Health Plus
- + Personal Wellness Plan (also known as Health and Recovery
- + Plan (HARP))
- + Essential Plans
- + Essential Plan 1
- + Essential Plan 2
- + Essential Plan 3
- + Essential Plan 4

- + Leaf and Leaf Premier Plans
- + Platinum Leaf and Platinum Leaf Premier
- + Gold Leaf and Gold Leaf Premier
- + Silver Leaf and Silver Leaf Premier
- + Bronze Leaf and Bronze Leaf Premier
- + Green Leaf
- + Total EPO Plans
- + Platinum Total EPO
- + Gold Total EPO
- + Silver Total EPO
- + Bronze Total EPO
- + Pro and Pro Plus Plans
- + Platinum Pro EPO and Platinum Pro Plus EPO
- + Gold Pro EPO and Gold Pro Plus EPO
- + Gold 25/50/0 Pro EPO and Gold 25/50/0 Pro Plus EPO
- + Gold 1350 Pro EPO and Gold 1350 Pro Plus EPO
- + Silver Pro EPO and Silver Pro Plus EPO
- + Silver 40/75/4700 Pro EPO and Silver 40/75/4700 Pro Plus EPO
- + Bronze Pro EPO and Bronze Pro Plus EPO
- + Bronze 6850 Pro EPO and Bronze 6850 Pro Plus EPO
- + Bronze 5250 Pro EPO

Please Note: Senior Health Partners (SHP), a managed long-term care plan, is excluded.



Medical Oncology Solution

The following types of drugs are included if being used to treat cancer, and if billed under the Medical or Pharmacy Benefit

- Infused, oral, and self-administered drugs in the primary treatment of cancer administered in the office or outpatient setting consistent with NCCN guidelines
- Select supportive agents included with the approved treatment regimen of cancer-related symptoms
- Companion diagnostics / precision medicine

To find a list of CPT codes that require prior authorization through EviCore, please visit: <u>Healthfirst Provider Resources | EviCore by Evernorth</u> **EviCore** By EVERNORTH



Submitting Requests



© 2025 eviCore healthcare. All Rights Reserved. This presentation contains Confidential and Proprietary information. Use and distribution limited solely to authorized personnel.

How to Request Prior Authorization

The EviCore Provider Portal is the easiest, most efficient way to request clinical reviews and check statuses.

- Save time: Quicker process than requests by phone or fax.
- Available 24/7.

EviCore

- **Save your progress**: If you need to step away, you can save your progress and resume later.
- **Upload additional clinical information**: No need to fax supporting clinical documentation; it can be uploaded on the portal.
- View and print determination information: Check case status in real time.
- **Dashboard**: View all recently submitted cases.
- **E-notification**: Opt to receive email notifications when there is a change to case status.
- **Duplication feature**: If you are submitting more than one request, you can duplicate information to expedite submissions.

To access the EviCore Provider Portal, visit www.EviCore.com



Phone: 888-801-1660 Monday – Friday 7 AM – 7 PM (local time)

Fax:866-466-6964

Utilization Management | Prior Authorization



Request is approved.

By EVERNORTH

Necessary Information for Prior Authorization

To obtain prior authorization on the very first submission, the provider submitting the request will need to gather information within four categories:



Referring (Ordering) Provider

- Physician name
- National provider identifier (NPI)
- Phone & fax number

Supporting Clinical

- Pertinent clinical information to substantiate medical necessity for the requested service
- CPT/HCPCS Code(s)
- Diagnosis Code(s)
- Previous test results

Rendering Facility

- · Facility name
- Address

EviCore By EVERNORTH

- National provider identifier (NPI)
- Tax identification number (TIN)

Member

Health Plan ID

Member name

Phone & fax number

Insufficient Clinical | Additional Documentation Needed

If during case build all required pieces of documentation are not received, or are insufficient for EviCore to reach a determination, the following will occur:

A hold letter will be faxed to the requesting provider requesting additional documentation.

The provider must submit the additional information to EviCore.

EviCore will review the additional documentation and reach a determination.

The hold letter will inform the provider about what clinical information is needed, as well as the **date by which it is needed**. Requested information must be received within the timeframe as specified in the hold letter, or EviCore will render a determination based on the original submission. Determination notifications will be sent.



Prior Authorization Outcomes, Special Considerations & Post-Decision Options



© 2025 eviCore healthcare. All Rights Reserved. This presentation contains Confidential and Proprietary information. Use and distribution limited solely to authorized personnel

Prior Authorization Outcomes

Determination Outcomes:

- Approved Requests: Authorizations are valid for up to 8-14 Months from the date of approval.
- Partially Approved Requests: In instances where multiple CPT codes are requested, some may be approved and some denied. In these instances, the determination letter will specify what has been approved as well as post decision options for denied codes, including denied Site of Care (if applicable).
- **Denied Requests:** Based on evidence-based guidelines, if a request is determined as inappropriate, a notification with the rationale for the decision and post decision/ appeal rights will be issued.

Notifications:

- Authorization letters will be faxed to the ordering provider.
- Web initiated cases will receive e-notifications when a user opts to receive.
- Members will receive a letter by mail.
- Approval information can be printed on demand from the EviCore portal: <u>www.EviCore.com</u>



EviCore

Special Circumstances

Alternative Recommendations

- An alternative recommendation may be offered, based on EviCore's evidence-based clinical guidelines.
- The ordering provider can either accept the alternative recommendation or request a reconsideration for the original request.
- Providers have up to **14 calendar days** to contact EviCore to accept the alternative recommendation.

Authorization Update

- If updates are needed on an existing authorization, you can contact EviCore by phone at 888-801-1660.
- While EviCore needs to know if changes are made to the approved request, any change could result in the need for a separate clinical review and require a new request (and the original approved request would need to be withdrawn).
- If the authorization is not updated, it may result in a claim denial.



EviCore By EVERNORTH

Post-Decision Options | Commerical Members

My case has been denied. What's next?

Your **determination letter** is the best immediate source of information to assess what options exist on a case that has been denied. You may also call EviCore to speak with an agent who can provide available option(s) and instruction on how to proceed.

Alternatively, select **All Post Decisions** under the **Authorization Lookup** function on **EviCore.com** to see available options.

Reconsiderations

EviCore

- Providers can request a reconsideration review.
- Reconsiderations must be requested within **14** calendar days after the determination date.
- Reconsiderations can be requested in writing or verbally via a Clinical Consultation with an EviCore physician.



Appeals

• EviCore will not process first-level appeals

Post-Decision Options |

Medicare Members

My case has been denied. What's next?

Clinical Consultation

- Providers can request a Clinical Consultation with an EviCore physician to better understand the reason for denial.
- Once a denial decision has been made, however, the decision cannot be overturned via Clinical Consultation.

Reconsideration

• Medicare cases **<u>do not</u>** include a reconsideration option.

Appeals

EviCore <u>will not</u> process first-level appeals for applicable members.





EviCore Provider Portal



© 2025 eviCore healthcare. All Rights Reserved. This presentation contains Confidential and Proprietary information. Use and distribution limited solely to authorized personnel.

EviCore Provider Portal | Access and Compatibility

Most providers are already saving time submitting clinical review requests online vs. telephone.

To access resources on the EviCore Provider Portal, visit EviCore.com/provider

Already a user? Log in with User ID & Password.

Don't have an account? Click Register Now.



EviCore's website is compatible with **all web browsers**. If you experience issues, you may need to **disable pop-up blockers** to access the site.



Creating an EviCore Provider Portal Account

Web Portal Preference					
Please select the Portal that is listed in your provider training material. This selection determines the primary portal that you will using to submit cases over the web.					
Default Portal*:	Select Select CareCore National				
User Information	Medsolutions				
All Pre-Authorization notifications	will be sent to the fax number and email address provided below	v. Please make sure you provide valid information.			
User Name*:		Address*:			
Email*:					
Confirm Email*:		City*:			
First Name*:		State*:	Select V Zip*:		
Last Name*:		Office Name:			

- Select CareCore National as the Default Portal.
- Complete the User Information section in full and **Submit Registration**.
- You will immediately be sent an email with a link to create a password. Once you have created a password, you will be redirected to the login page.

EviCore

By EVERNORTH

Setting Up Multi-Factor Authentication (MFA)

To safeguard your patients' private health information (PHI), we have implemented a multi-factor authentication (MFA) process.

- After you log in, you will be prompted to register your device for MFA.
- Choose which authentication method you prefer: Email or SMS. Then, enter your email address or mobile phone number.
- Once you select **Send PIN**, a 6-digit pin will be generated and sent to your chosen device.
- After entering the provided PIN in the portal display, you will successfully be authenticated and logged in.

	Email 🔘 SMS
Register En	nail Address
example@	evicore.com
Only one device	e (Email or SMS) is currently allowed.
Please ente Address	er PIN sent to your Email
PIN	



Welcome Screen | Adding Providers to Registration



- Providers can be added to your account prior to case submission.
- Click the Manage Your Account tab to add providers to the web registration.

Welco	me to the CareCore National Web Portal. You are logged in as
	REQUEST AN AUTH
	RESUME IN-PROGRESS REQUEST
	SUMMARY OF AUTH
	AUTH LOOKUP
	MEMBER ELIGIBILITY













Requesting Provider Information

Select the ordering provider for this authorization request.

The Office user will select the treating physician from their pre-populated affiliated physician list.

Your account currently has no active providers. Please use the search feature below to add providers to your account and proceed with case build.

Search By NPI: s	EARCH		
			Provider
BACK CONTINUE		SELECT	1063644797 - BELICENA, MARIA THERES
Click have fee hale		SELECT	1275548018 - BERGQUIST, SHARON
Click here for help		SELECT	1386733871 - SHERMAN, WILLIAM
		SELECT	1588812242 - SMITH, DAVID
© CareCore National, LLC. 2024 All rights reserved.	SELECT	1396862892 - STAPLES, SUZANNE	
Privacy Policy Terms of Use Contact Us			



Choose Your Insurer

Requesting Provider: BELICENA, MARIA THERESA, NPI 1063644797

Please select the insurer for this authorization request.



Click here for help

Urgent Request? You will be required to upload relevant clinical info at the end of this process. Learn More.

Don't see the insurer you're looking for? Please call the number on the back of the member's card to determine if an authorization through eviCore is required.

Select the patient's health plan.



© 2025 eviCore healthcare. All Rights Reserved. This presentation contains Confidential and Proprietary information. Use and distribution limited solely to authorized personnel.

Choose Your Insurer

Requesting Provider: BELICENA, MARIA THERESA, NPI 1063644797

Please select the insurer for this authorization request.

PLAN-X	۲
2566 HAYMAKER RD	•



Click here for help

Urgent Request? You will be required to upload relevant clinical info at the end of this process. Learn More.

Don't see the insurer you're looking for? Please call the number on the back of the member's card to determine if an authorization through eviCore is required.

Take note of any important messages

and confirm the provider address.



© 2025 eviCore healthcare. All Rights Reserved. This presentation contains Confidential and Proprietary information. Use and distribution limited solely to authorized personnel.

Add Your Contact Info



carriers.carecorenational.com says

Please review the fax and phone numbers presented for accuracy. Change as necessary and click CONTINUE to confirm they are correct. Changes apply only to this specific case. If you wish the change to be permanent, please contact the Health Plan.

ОК

Contact information is confirmed or entered to ensure smooth communication of the determination or to request additional information as needed.



Patient Eligibility Lookup

EviCore By EVERNORTH

New Patient Registration	Current	t Patients			
Member ID (no spaces or dashes) Date of Birth (MM/DD/YYYY) Last Name First Name (optional)	Filter by Physician All Providers ✔ User or provider has no patients	New patients are registered and eligibility is verified a			
SEARCH CANCEL Provider: 1063644797 - Health Plan: PLAN-X Member ID: 530385101 Date of Birth: 3/20/197 Name: VACCA,DARYL City, State: Verona, NJ Do you want to continue YES No	ent Registration BELICENA, MARIA THERESA 01 1 1 e with this patient?	confirmation so appear. Click continue.	reen will "Yes" to		

Attention!	
Patient ID: 6428032324 Patient Name: HAGEDORN, POI	Time: 1/24/2024 2:28 PM
Please provide the patient's be (555)555-5555	st contact number including area code.
SUBMIT	Provide the patient's best contact number. Click "submit" to continue.



Clinical Certification

NADINE DELAET	6/13/1987
354 NUOVO RD	Age: 36
CHESTNUT HILL, MA 02467	Male
CIGNA ID 250251652	

The Patient History Screen becomes the hub for all future requests or data relating to this patient. Including a record of previous requests for services through eviCore, authorization numbers and dates, and clinical summaries based on the information provided through the request process.

NEW REVIEW

Reviews								
Date	Physician	Case #	Cancer Type	Therapy	Treatment	Status		
1/29/2024	BELICENA, MARIA	1184813089	Undetermined	Primary	Undetermined	Expired		VIEW HISTORY
I						I		K

Click to view clinical information, Jcodes, and expiration date.



Attention! Patient ID : 8504027002 Time: 3/4/2019 2:02 f	PM
Patient Name: Lulu Marcell What is the anticipated start date of treatment?	CHEMO – Chemotherapy: Select this option for primary therapy; when the drug/regimen is being used to treat the cancer itself. If you need supportive drugs as well, you will have an option to request those at the end of the primary therapy request. SPORT – Supportive: Select this option when the drug(s) are being used to prevent or treat the side effects of the primary therapy (example: anti-emetics).
Enter: Start Date of Treatment Take note of important message describing CHEMO and SPORT.	OK





Requested Service + Diagnosis

This procedure will be performed on 1/26/2024.

CHANGE

Medical Oncology Pathways

Select a Procedure by CPT Code[?] or Description[?] CHEMO
CHEMOTHERAPY
CHEMOTHERAPY
Con't see your procedure code or type of service? Click here
Primary Chemotherapy and Supportive drugs must be entered as separate requests.

Diagnosis

Primary Diagnosis Code: **153.1** Description: **Malignant neoplasm of transverse colon** <u>Change Primary Diagnosis</u>

Select a Secondary Diagnosis Code (Lookup by Code or Description) Secondary diagnosis is optional for Medical Oncology Pathways



Select ICD10 by entering code or description. Select "Continue".



Requested Service + Diagnosis

Confirm your service selection.

Procedure Date:1/26/2024Medical Oncology Pathways:CHEMODescription:CHEMOTHERAPYPrimary Diagnosis Code:153.1Primary Diagnosis:Malignant neoplasm of transverse colonSecondary Diagnosis:Secondary Diagnosis:Change Procedure or Primary DiagnosisSister Secondary DiagnosisChange Secondary DiagnosisSister Secondary Diagnosis

BACK CONTINUE

	Yes		(No
•	Confirm or use the back and needed. Answer billed ur the orde	the inf he 'cha d make if treat nder the ering pr	formati inge' li e corre ments e same rovider	ion ent nks to ections will be e TIN a

Add Site of Service Specific Site Search Use the fields below to search for specific your entry. NPI: 1063644797 TIN:	c sites. For best results, search by NPI or TIN. Other search options are by name plus zip or name plus city. You may s Zip Code: 34613 City:	earch a partial sit Site	Distinct rendering site or facility can be entered if needed. Multiple lookup options are available. Network logic can be applied as needed.
	Name		Address
SELECT	BELICENA MARIA	11375 CORTEZ BI BROOKSVILLE, FL	LVD .34613
SELECT	BELICENA MARIA	10065 CORTEZ BI BROOKSVILLE, FL	LVD .34613
SELECT	BELICENA MARIA	10065 CORTEZ BI BROOKSVILLE, FL	LVD 34613
SELECT	BELICENA MARIA	11375 CORTEZ BI BROOKSVILLE, FL	LVD .34613
	·		

BACK



EviCore





Summary of Your Request

Please review the details of your request below and if everything looks correct click CONTINUE

The Diagnosis code selected is for a non-cancer indication which is not in scope for the Medical Oncology program at eviCore. This case will be expired. Please contact the health plan if you have any questions. **Provider Name:** DR. MARIA BELICENA В Contact: Provider Address: 11375 CORTEZ BLVD Phone Number: (352) 596-4660 BROOKSVILLE, FL 34613 Fax Number: (555) 555-5555 Patient Name: NADINE DELAET Patient Id: 250251652 Insurance Carrier: CIGNA Site Name: BELICENA MARIA Site ID: **NPLIKQ** Site Address: 10065 CORTEZ BLVD BROOKSVILLE, FL 34613 Primary Diagnosis Code: 153.1 Description: Malignant neoplasm of transverse colon Secondary Diagnosis Code: Description: Date of Service: 1/31/2024 CPT Code: CHEMO CHEMOTHERAPY Description: 1184813089 Case Number: 1/29/2024 12:26:26 PM **Review Date:** Expiration Date: N/A Status: The Diagnosis code selected is for a non-cancer indication which is not in scope for the Medical Oncology program at eviCore. This case will be expired. Please contact the health plan if you have any questions. CONTINUE CANCEL PRINT Continue if "Summary" looks Click here for help correct.

EviCore By EVERNORTH

Proceed to Clinical Information

The demographic portion of the case is complete. Reminders on how to complete the clinical portion are displayed. Click 'Continue to proceed to the clinical review.

You are about to enter the clinical information collection phase of the author C

After answering the clinical question(s) on each screen you will need to hit the CINICAL TEVIEW. of the clinical questions you must hit "Submit" before exiting the system. You will be asked to attest to the clinical information that you have provided. Hit "Submit" and your request for a prior authorization will be submitted for review.

Your answers to previous questions will be displayed on the lower portion of the screen. If you made an error during the clinical data collection process you can click on the question. The system will ask that you answer the question again and subsequent questions. You can use the "Finish Later" button, for Standard/Routines cases only, to save information and return to this case at a later time. This will save all case information recorded up to but not including the current screen.

Failure to formally submit your request by clicking the "Submit" button after the attestation will cause the request for a prior authorization to expire with no additional correspondence.

BACK CONTINUE



Proceed to Clinical Information

Is this case Routine/Standard?



Proceed to Clinical Information

— Urgency Indicator

If the case you are submitting is found NOT to meet one of the two conditions below, your case will be processed as a standard/routine, non Urgent request. If you have clinical information and this request meets the criteria for urgent, please indicate below.

In order for eviCore to process this case as clinically urgent you must upload clinical documentation relevant to this case. If you are unable to upload clinical documentation at this time contact eviCore to process this case as urgent.

Please indicate if any of the following criteria are true regarding urgency of this request :

○ A delay in care could seriously jeopardize the life or health of the patient or patient's ability to regain maximum function.

O A delay in care would subject the member to severe pain that cannot be adequately managed without the care or treatment requested in the prior authorization.

None of the above



© 2025 eviCore healthcare. All Rights Reserved. This presentation contains Confidential and Proprietary information. Use and distribution limited solely to authorized personnel.

Answer if the request is "Routine/Standard". If no, select "Urgency Indicator".

Proceed to Clinical Information

EviCore

By EVERNORTH



© 2025 eviCore healthcare. All Rights Reserved. This presentation contains Confidential and Proprietary information. Use and distribution limited solely to authorized personnel.

Exclusions are confirmed.

Proceed to Clinical Information

O Please select all of the following that apply:

The patient is participating in a clinical trial that includes cancer treatment drugs The requested drug is being used to treat a condition other than cancer

☐ The treatment will be administered inpatient

□ CAR-T Therapy □ None of the above

□ This request is for a Stem Cell Transplant conditioning regimen

SUBMIT



Proceed to Clinical Information

Please select the Place of Service for this request:
Off Campus-Outpatient Hospital
On Campus-Outpatient Hospital
Outpatient Home

SUBMIT



Proceed to Clinical Information

Was the patient initially diagnosed with metastatic disease beyond locoregional nodes?
 ○Yes ○ No

SUBMIT

Proceed to Clinical Information

Has the disease persisted, progressed or recurred?
 OYes ○ No

Proceed to Clinical Information

Most recent entry for this patient: None

- What is the histology of the cancer?
 Papillary carcinoma
 Follicular carcinoma
 Oncocytic cell carcinoma
 Madullary carcinoma
- O Medullary carcinoma
- Anaplastic carcinoma

SUBMIT

Proceed to Clinical Information

Inter the month and year of initial diagnosis in the format mm/yyyy. If the month is not known enter "00" for MM.

SUBMIT

SUBMIT

the cancer. The system will dynamically filter to only the minimum number of questions needed to complete the review.
Almost all answers are in drop down or click selection to allow for quick entry and structured data for reporting and analysis.

The office user will be asked

necessary to generate the

recommended treatment list

for the patient being treated.

A typical traversal will have

based on the complexity of

between 5 and 12 questions

a series of questions

EviCore By EVERNORTH

Proceed to Clinical Information

The National Comprehensive Cancer Network[®] (NCCN[®]) believes that the best management for any patient with cancer is in a clinical trial and that participation in clinical trials is especially encouraged. In some situations, trial participation may not be included in the patient's benefit plan design.

The following list represents potential treatment clinical trial matches in active and open enrollment status for this patient based on a search of the National Cancer Institute's (NCI) clinical trial database using the information gathered in this prior authorization request.

Trials are sorted in order of proximity between the patient's ZIP code and the nearest participating provider. This search result is limited to a maximum of 50. Please visit the NCI website www.cancer.gov if you would like to expand your search. By default, the following search result is filtered to Phase 2 and 3 clinical trials. You may customize the search result to particular states and clinical trial phases using the filters below.

If you would like more information on any of the clinical trials displayed, select the clinical trial(s) of interest, using the checkbox on the left and click "SUBMIT" to have more information sent to you. You may also click on the corresponding Trial ID and a new browser window will open with more information on that trial.

If you do not wish to receive more information on any clinical trials, click "SUBMIT" to continue without selecting any of the checkboxes.

If your patient's tumor contains a genetic abnormality, the MATCH (NCT02465060) and TAPUR (NCT02693535) clinical trials offer investigational targeted drug therapies for a wide variety of cancers.

Links

- MATCH
- <u>TAPUR</u>

0

SUBMIT

All NCCN recommended treatments are displayed. This can be modified to display a filtered list based on level of evidence or other factors at Cigna's request.

EviCore

Proceed to Clinical Information

The treatment options listed below reflect the recommendations of the National Comprehensive Cancer Network (NCCN) based on the clinical information submitted. Febrile Neutropenia and Emetic Risk are sourced from the NCCN Guidelines and supplemented by supporting literature.

By selecting an NCCN regimen you will be granted an immediate authorization.* If a Pathway regimen is not selected, a peer consultation with an eviCore Medical Director may be required.

*Other policies may apply in select situations.

You will be given the ability to select biosimilar products - when available - after first selecting your regimen below.

Select Treatment Option:

All NCCN recommended
treatments are displayed.
This can be modified to
display a filtered list
based on level of
evidence or other factors
at Cigna's request.

	Regimen	Pathway	Febrile Neutropenia Risk	Emetic Risk
\bigcirc	VAIA: (Vincristine + Doxorubicin (alternating with Dactinomycin + Ifosfamide + mesna)		High	High
\bigcirc	VDC/IE (Vincristine + Doxorubicin HCL + Cyclophosphamide + Ifosfamide + Etoposide)		High	High
0	VIDE (Vincristine + Ifosfamide + Doxorubicin HCL (or Dactinomycin) + Etoposide)		High	High
0	Build a Custom Treatment Plan (May Require Additional Clinical Review)			

SUBMIT

The system is designed to managed injectable chemotherapy only or injectable + oral chemotherapy This will be decided as part of the program design conversation.

EviCore By EVERNORTH

Proceed to Clinical Information

5-Fluorouracil (Adrucil, SEU, SEU, Adrucil)

Select the chemotherapy drug(s) for the treatment regimen from the Drug List below.

- If you are able to select the treatment option using the Drug List, provide administration schedule and select "SUBMIT" to continue to the ne
- If a chemotherapy drug is not on this list, and it is a newly approved chemotherapy drug that will be billed with a miscellaneous code, please treatment regimen.

Custom Treatment plans can be submitted for any case where the provider does not want to use a recommended regimen. Drugs are selected from a drop down list and the user has the opportunity to attach or enter supporting

on

🗆 5FU (5-Fluorouracil)	🗌 Lynparza (Olaparib - oral)	user has the opportunity to
🗆 5FU (5-Fluorouracil)	🗌 Lytgobi (Futibatinib - oral)	attach or enter supporting
🗌 Abemaciclib - oral (Verzenio)	🗌 Lytgobi (Futibatinib - oral)	
Abiraterone Acetate - oral (Zytiga, Zytiga)	🗌 Margenza (Margetuximab-cmkb)	information for the request.
Abir Abiraterone Acetate - oral (Zytiga, Zytiga) , Yonsa)	Margetuximab-cmkb (Mar Proceed to Clinical In	forma
🗌 Abraxane (Paclitaxel (albumin-bound))	Mekinist (Trametinib - oral Is there any additional clinical info	ormation you would like to submit at this time?
🗌 Abraxane (Paclitaxel (albumin-bound))	Mekinist (Trametinib - oral Documentation to support your p	roposed treatment should be submitted in the following manner:
🗌 Abraxane (Paclitaxel (albumin-bound))	Mekinist (Trametinib - oral · Free text in box below · Attach documentation to case	
🗌 Abraxane (Paclitaxel (albumin-bound))	Mektovi (Binimetinib - ora If you need additional time, click '	'Save and Exit" and return by clicking "RESUME".
Acalabrutinib - oral (Calquence, Calquence)	Mektovi (Binimetinib - ora Click 'Submit' if you have no addit	ional clinical information to add at this time.
🗌 Actemra (Tocilizumab)	Melphalan HCL - inj (Alker O Enter Supporting Clinical Inform	nation in the field below:
 Actimmune (Interferon, gamma-1b) 	🗌 Melphalan HCL (Evomela)	
🗌 Adagrasib - oral (Krazati)	Methotrexate (accord)	
🗌 Adcetris (Brentuximab Vedotin)	🗌 Midostaurin - oral (Rydapt	
🗌 Ado-Trastuzumab Emtansine (Kadcyla)	🗌 Mirvetuximab Soravtansin	
🗌 Adriamycin (Doxorubicin HCL)	Mitomycin (Jelmyto) You may attach up to 5 documen	ے ts no larger than 5 MB each (25 MB total). Click "Browse" to select the document from your desktop or other network locat
🗌 Adrucil (5-Fluorouracil)	Mitomycin (Mutamycin, N Allowable file formats:	
🗌 Adrucil (5-Fluorouracil)	Mitoxana (Ifosfamide) .poc, .pocx, .pdf, .jpg, .jpeg, .r	іғ, .тхт
	• Attach a document:	
	Choose File No file chosen	

□ Lynparza (Olaparib - oral)

EviCore By EVERNORTH

Orug List:

Proceed to Clinical Information

Proceed to Clinical Information

Please confirm the clinical information provided below is correct and click "submit" to complete your request.

SUBMIT

Patient weight in pounds:

Patient height in inches:

Continue answering additional **Proceed to Clinical Information** questions and confirm it is accurate. I acknowledge that the clinical information submitted to support this authorization request is accurate and specific to this member, and that all information has been provided. I have no further information to provide at this time. SUBMIT

SUBMIT CASE

Click here for help



Summary of Your R	equest ur request below and if a	Review Summary of your Request"	IUE		Selection of a recommended regimen will result in immediate approval of all
The prior authorization y	you submitted, Case Az		a. Additional case st	tatus notifications will be sent if you opter	drugs in the requested
Provider Name: Provider Address:	DR. MARIA BELIC 11375 CORTEZ BL BROOKSVILLE, FL	ENA VD 34613	Contact: Phone Number: Fax Number:	B (555) 555-5555 (555) 555-5555	regimen with an authorization time span sufficient to
Patient Name: Insurance Carrier:	MARSHA COLETR CIGNA	ANE	Patient Id:	U25153824	treatment. No further action
Site Name: Site Address:	REX HOSPITAL IN 850 S MAIN ST HOLLY SPRINGS, 1	C NC 27540	Site ID:	OOL22K	is needed unless the treatment needs to be changed due to disease
Primary Diagnosis Code: Secondary Diagnosis Code:	C50.412		Descrip ti on: Descrip ti on:	Malignant neoplasm of upper-outer quadran	progression or other clinical
Date of Service: HCPCS Code(s): Authorization Number: Review Date:	2/2/2024 J9267, Q5114 A200580140 1/30/2024 1:59:5	9 PM	Drug(s):	PACLITAXEL (TAXOL, NOV-ONXOL, TAXOL, NO	factors.
Expiration Date: Status:	4/2/2025 Your case has bee The prior authori	n APPROVED. zation you submitted, Case A200	0580140, has been rece	ived. Additional case status notifications will be	sent if you opted in for email notifications. Thank you.
CANCEL PRINT	GO TO PATIENT HISTO		/ES		

EviCore By EVERNORTH

Summary of Your Request

Please review the details of your request below and if everything looks correct click CONTINUE

Your case has been APPROVED.

The prior authorization you submitted, Case A200580140, has been received. Additional case status notifications will be sent if you opted in for email notifications. Thank you.

Provider Name: Provider Address:	DR. MARIA BELICENA 11375 CORTEZ BLVD BROOKSVILLE, FL 34613		Contact: Phone Number: Fax Number:	B (555) 555-5555 (555) 555-5555	The next few slides will provide guidance on		
Patient Name:	MARSHA COLETRANE		Patient Id:	U25153824	requesting Supportive Drugs		
Insurance Carrier:	CIGNA						
Site Name:	REX HOSPITAL INC		Site ID:	OOL22K			
Site Address:	850 S MAIN ST						
	HOLLY SPRINGS, NC 275	40					
Primary Diagnosis Code: C50.412 Descr		Description:	on: Malignant neoplasm of upper-outer quadrant of left female breast				
Secondary Diagnosis Code:			Description:				
Date of Service:	2/2/2024						
HCPCS Code(s):	J9267, Q5114		Drug(s):	PACLITAXEL (TAXOL, NOV	-ONXOL, TAXOL, NOV-ONXOL), TRASTUZUMAB-DKST (OGIVIRI)		
Authorization Number:	A200580140						
Review Date:	1/30/2024 1:59:59 PM						
Expiration Date:	4/2/2025						
Status:	Your case has been APP	ROVED.					
	The prior authorization	you submitted, Case A20058	0140, has been rec	oived Additional case status	notifications will be cont if you opted in for email notifications. Thank you.		
				Request for Su	upportive"		
CANCEL PRINT	GO TO PATIENT HISTORY	REQUEST SUPPORTIVES		drugs can be ir	nitiated		
				nere			
Core							

Attention!

CHEMO – Chemotherapy: Select this option for primary therapy; when the drug/regimen is being used to treat the cancer itself. If you need supportive drugs as well, you will have an option to request those at the end of the primary therapy request. SPORT – Supportive: Select this option when the drug(s) are being used to prevent or treat the side effects of the primary therapy (example: anti-emetics).



Read through attention messages to confirm request.



Requested Service + Diagnosis

Confirm your service selection.

Procedure Date:	1/31/2024					
Medical Oncology Pathways: SPORT						
Description:	SUPPORTIVE THERAPIES					
Primary Diagnosis Code:	C11.1					
Primary Diagnosis:	Malignant neoplasm of posterior wall of nasopharynx					
Secondary Diagnosis Code:						
Secondary Diagnosis:						
Change Procedure or Primary Diagnosis						
Change Secondary Diagnosis						
BACK CONTINUE						

Click here for help

If "Request Supportives" is selected, a new case is started and the user is dropped on this screen to complete a supportive drug request. The start date, drug classification, and ICD10 are prepopulated to match the Chemotherapy case. Click Continue to proceed to the clinical portion of the request







Bevacizumab (Alymsys) Bevacizumab (Mvasi)

Bevacizumab (Vegzelma) Bevacizumab (Zirabev) Burosumab (Crysvita)

Denosumab (Prolia)

Denosumab (Xgeva) MONTHLY

Dronabinol (Syndros) Oral Solution Eflapograstim-xnst (Rolvedon)

Proceed to Clinical Information

Darbepoetin alfa (Aranesp) ONCE EVERY 2 WEEKS Darbepoetin alfa (Aranesp) ONCE EVERY 3 WEEKS

Darbepoetin alfa (Aranesp) WEEKLY FIXED DOSE

Denosumab (Xgeva) MONTHLY and DAY 8, 15

Darbepoetin alfa (Aranesp) WEEKLY WEIGHT BASED DOSE

Indicate the requested supportive agent:

Proceed to Clinical Information

Indicate the Cancer Type:

Colon/Rectal Cancer

SUBMIT

Proceed to Clinical Information

Which class of drugs do you intend to treat with?
 Antiemetic agents
 Other supportive agents (such as erythropoiesis-stimu)



User will be asked to indicate the drug needed and may be asked for additional clinical information to support that request. If multiple supportive drugs are needed a separate request must be entered for each drug.

TIMES PER WEEK DNCE EVERY 2 WEEKS DNCE EVERY 3 WEEKS VEEKLY IMES PER WEEK

EviCore By EVERNORTH

© 2025 eviCore healthcare. All Rights Reserved. This presentation contains Confidential and Proprietary information. Use and distribution limited solely to authorized personnel.

Summary of Your Request

Please review the details of your request below and if everything looks correct click CONTINUE

Request does not contain any drugs managed for this member under this program.

Provider Name: Provider Address:			Contact: Phone Number: Fax Number:	
Patient Name: Insurance Carrier:			Patient Id:	
Site Name: Site Address:		The summary screen confirms that status and details of the request):	684GQZ
Primary Diagnosis Code:	C00.0	details of the request.	Description:	Malignant neoplasm of external upper lip
Secondary Diagnosis Code:			Description:	
Date of Service:	2/2/2024			
CPT Code:	CHEMO		Description:	CHEMOTHERAPY
Case Number:	1184814046			
Review Date:	1/30/2024 10:21:35 AM			
Expiration Date:	N/A			
Status:	Request does not contain any d	lrugs managed for this member under this program.		

CANCEL PRINT GO TO PATIENT HISTORY

REQUEST SUPPORTIVES

EviCo By EVERNORTH

© 2025 eviCore healthcare. All Rights Reserved. This presentation contains Confidential and Proprietary information. Use and distribution limited solely to authorized personnel.



March 14, 2025 54